½ÃÀ庸°í¼­
»óǰÄÚµå
1375139

ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¿¹Ãø(-2028³â) : Áö¿ªº° ºÐ¼® - Á¦Ç° À¯Çü, ÀÀ¿ë ºÐ¾ß ¹× ÃÖÁ¾ »ç¿ëÀÚº°

North America Neurotoxins Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product Type, Application, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 99 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº 2023³â 48¾ï 129¸¸ ´Þ·¯¿¡¼­ 2028³â 84¾ï 1,695¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³âºÎÅÍ 2028³â±îÁö 11.9%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Çõ½ÅÀûÀÎ ÆäÀÌ¼È ¿¡½ºÅׯ½ Á¦Ç°ÀÇ µîÀåÀ¸·Î ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå Ȱ¼ºÈ­

Àüü ½Å°æµ¶ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¾È¸é ¹Ì¿ë¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ±âÇϱ޼öÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³â 3¿ù, Aquavit Pharmaceuticals, Inc. ÀÓ»ó½ÃÇè¿ë ½Å¾à(IND) ½ÅûÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¦Ç°Àº Ŭ·Î½ºÆ®¸®µð¿ò º¸Åø¸®´®±ÕÀÌ »ý»êÇÏ´Â ½Å°æµ¶¿¡¼­ À¯·¡ÇÑ 900kDaÀÇ ´Ü¹éÁú º¹ÇÕü¸¦ °í¼øµµ·Î Á¤Á¦ÇØ ÀÓ»ó½ÃÇèÀ» ¿Ï·áÇÑ ÁÖ»çÁ¦Çü ½Å°æÁ¶ÀýÁ¦ÀÔ´Ï´Ù. ¶ÇÇÑ, ¾ÆÄí¾ÆºñÆ®´Â DTX-022¸¦ µµÀÔÇØ ÀÓ»óÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, ÃÖÁ¾ ½ÂÀÎ ½Ã ¼¼°è ÃÖÃÊÀÇ ¹ü¾È¸é ¹Ì·®ÁÖ»çÁ¦ ½Å°æµ¶À¸·Î ÀÎÁ¤¹Þ°Ô µË´Ï´Ù. ¸¶Âù°¡Áö·Î, üÁß °¨·® Æ®·»µå°¡ Áö¼ÓµÇ¸é¼­ ºñħ½ÀÀû ½Ã¼úÀ» ¿øÇϴ ȯÀÚµé »çÀÌ¿¡¼­ À§ º¸Å彺°¡ Àαâ ÀÖ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. À§ º¸Å彺´Â ³»½Ã°æ ±â¼úÀ» ÅëÇØ ƯÁ¤ À§ ºÎÀ§¿¡ º¸Å彺¸¦ ÁÖÀÔÇÏ´Â ½Ã¼úÀÔ´Ï´Ù. ÀÌ ±â¼úÀº À§ ±ÙÀ°ÀÇ ¼öÃàÀ» Á¦ÇÑÇÕ´Ï´Ù. ÀÌ Á¦ÇÑÀ¸·Î ÀÎÇØ À§ ¹èÃâ °úÁ¤¿¡ ½Ã°£ÀÌ °É¸®±â ¶§¹®¿¡ ȯÀÚ´Â ´õ ¿À·¡ Æ÷¸¸°¨À» ´À³¥ ¼ö ÀÖÀ¸¸ç, ±× °á°ú ½Ä¿åÀÌ °¨¼ÒÇÏ°í °íÇ÷¾Ð, ´ç´¢º´°ú °°Àº üÁß °ü·Ã °Ç°­ ¹®Á¦ ¹× »ýȰ½À°üº´À» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ Çõ½ÅÀûÀÎ ¾È¸é ¹Ì¿ë Á¦Ç°ÀÇ ÃâÇöÀº ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀÇ ¼ºÀå¿¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå °³¿ä

ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº ½Å°æµ¶ÀÇ °¡Àå Å©°í ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀÔ´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº Á¦Ç° Ãâ½Ã Áõ°¡, ´Ù¾çÇÑ ±ÙÀ° Áúȯ¿¡ ´ëÇÑ ½Å°æµ¶ÀÇ FDA ½ÂÀÎ Áõ°¡, °í·ÉÈ­ Àα¸ Áõ°¡, ºñ¼ö¼úÀû ¶Ç´Â Àúħ½ÀÀû ¹Ì¿ë ½Ã¼ú Áõ°¡, ¹Ì¿ë ½Ã¼ú Áõ°¡, Àúħ½ÀÀû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¼öÀÍ ¹× 2028³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¼¼ºÐÈ­

ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ºÐ·ùµË´Ï´Ù. Á¦Ç° À¯Çü¿¡ µû¶ó ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº º¸Å彺, µð½ºÆ÷Æ®, Á¦³ë¹Î ¹× ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù. º¸Å彺 ºÎ¹®Àº 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

¿ëµµº°·Î ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº Ä¡·á¿ë°ú ¹Ì¿ë¿ëÀ¸·Î ±¸ºÐµÇ¸ç, 2023³â¿¡´Â Ä¡·á ºÎ¹®ÀÌ ´õ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº º´¿ø, Àü¹® Ŭ¸®´Ð, ÇǺΰú Ŭ¸®´Ð, ±âŸ·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®ÀÌ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î´Â ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹ÀÌ 2023³â ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, Merz Pharma GmbH &Co KGaA, Metabiologics, Revance Therapeutics Inc µîÀÌ ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå - ¿äÁ¡

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå - ½ÃÀå ±¸µµ

  • °³¿ä
  • ºÏ¹ÌÀÇ PEST ºÐ¼®
  • Àü¹®°¡ÀÇ °ßÇØ

Á¦5Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ÇâÈÄ µ¿Çâ
  • ¿µÇ⠺м®

Á¦6Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå

  • ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¸ÅÃâ ¿¹Ãø°ú ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø-À¯Çüº°

  • ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå À¯Çüº° ¸ÅÃâ Á¡À¯À²(2022³â, 2028³â)
  • Botox
  • Dysport
  • Xeomin
  • ±âŸ

Á¦8Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå : ¿ëµµº° ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø

  • ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¿ëµµº° ÆÇ¸Å·® Á¡À¯À²(2022³â ¹× 2028³â)
  • Therapeutic
  • Aesthetic

Á¦9Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃâ°ú 2028³â ¿¹Ãø

  • ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃâ Á¡À¯À²(2022³â ¹× 2028³â)
  • º´¿ø
  • ¸ÞµðÄà ½ºÆÄ ¹× ¹Ì¿ë ¼¾ÅÍ
  • ÇǺΰú Ŭ¸®´Ð
  • ±âŸ

Á¦10Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø : ±¹°¡º° ºÐ¼®

    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ

Á¦11Àå ºÏ¹ÌÀÇ ½Å°æµ¶ ½ÃÀå - ¾÷°è »óȲ

  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦12Àå ±â¾÷ °³¿ä

  • Merz Pharma GmbH & Co KGaA
  • AbbVie Inc
  • Revance Therapeutics Inc
  • Ipsen SA
  • Medytox Inc
  • Hugel Inc
  • Metabiologics

Á¦13Àå ºÎ·Ï

LSH 23.11.14

The North America neurotoxins market is expected to grow from US$ 4,801.29 million in 2023 to US$ 8,416.95 million by 2028. It is estimated to grow at a CAGR of 11.9% from 2023 to 2028.

Emergence of Innovative Facial Aesthetic Products Fuels North America Neurotoxins Market

The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of "DTX-021"-a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world's first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the North America neurotoxin market to grow.

North America Neurotoxins Market Overview

The North America neurotoxin market is segmented into the US, Canada, and Mexico. The US is the largest and fastest-growing market for neurotoxins. The market growth in the region is attributed to the increasing product launches, growing FDA approvals for neurotoxins for various muscular conditions, rising aging population, increasing numbers of non-surgical or minimally invasive cosmetic procedures, increasing number of aesthetic procedures, and growing demand for minimally invasive therapeutics.

North America Neurotoxins Market Revenue and Forecast to 2028 (US$ Million)

North America Neurotoxins Market Segmentation

The North America neurotoxins market is segmented into product type, application, end user, and country. Based on product type, the North America neurotoxins market is sub segmented into botox, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.

Based on application, the North America neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held a larger market share in 2023.

Based on end user, the North America neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.

Based on country, the North America neurotoxins market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2023.

AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, Merz Pharma GmbH & Co KGaA, Metabiologics, and Revance Therapeutics Inc are among the leading companies operating in the North America neurotoxins market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America neurotoxins market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the North America neurotoxins market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the neurotoxins market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 North America Neurotoxin Market - by Type
    • 1.3.2 North America Neurotoxin Market - by Application
    • 1.3.3 North America Neurotoxin Market - by End User
    • 1.3.4 North America Neurotoxin Market - by Country

2. North America Neurotoxin Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Neurotoxin Market - Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis
  • 4.3 Expert Opinion

5. North America Neurotoxin Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Surge in Cosmetic Procedures to Improve Appearance
    • 5.1.2 Emergence of Innovative Facial Aesthetic Products
  • 5.2 Market Restraints
    • 5.2.1 Improper/Inappropriate Injection Technique
  • 5.3 Market Opportunities
    • 5.3.1 Neurotoxins to Reduce Spasticity in Upper Limb Muscles
  • 5.4 Future Trends
    • 5.4.1 BOTA for Assisted Reproductive Technology (ART)
  • 5.5 Impact Analysis

6. North America Neurotoxin Market

  • 6.1 North America Neurotoxin Market Revenue Forecast and Analysis

7. North America Neurotoxin Market - Revenue and Forecast to 2028 - By Type

  • 7.1 Overview
  • 7.2 North America Neurotoxin Market Revenue Share, by Type (2022 and 2028)
  • 7.3 Botox
    • 7.3.1 Overview
    • 7.3.2 Botox: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Dysport
    • 7.4.1 Overview
    • 7.4.2 Dysport: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Xeomin
    • 7.5.1 Overview
    • 7.5.2 Xeomin: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Neurotoxin Market - Revenue and Forecast to 2028 - By Application

  • 8.1 Overview
  • 8.2 North America Neurotoxin Market Revenue Share, by Application (2022 and 2028)
  • 8.3 Therapeutic
    • 8.3.1 Overview
    • 8.3.2 Therapeutic: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Aesthetic
    • 8.4.1 Overview
    • 8.4.2 Aesthetic: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Neurotoxin Market - Revenue and Forecast to 2028 - By End User

  • 9.1 Overview
  • 9.2 North America Neurotoxin Market Revenue Share, by End User (2022and 2028)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Medical Spas and Beauty Centers
    • 9.4.1 Overview
    • 9.4.2 Medical Spas and Beauty Centers: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Dermatology Clinics
    • 9.5.1 Overview
    • 9.5.2 Dermatology Clinics: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: North America Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)

10. North America Neurotoxin Market -Revenue and Forecast to 2028- Country Analysis

  • 10.1 Overview
    • 10.1.1 North America: Neurotoxin Market, by Country, 2022& 2028 (%)
      • 10.1.1.1 US: Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 US: Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.3 US: Neurotoxin Market, by Product Type, 2020-2028 (US$ Million)
        • 10.1.1.1.4 US: Neurotoxin Market, by Application, 2020-2028 (US$ Million)
        • 10.1.1.1.5 US: Neurotoxin Market, by End User, 2020-2028 (US$ Million)
      • 10.1.1.2 Canada: Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 Canada: Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.3 Canada: Neurotoxin Market, by Product Type, 2020-2028 (US$ Million)
        • 10.1.1.2.4 Canada: Neurotoxin Market, by Application, 2020-2028 (US$ Million)
        • 10.1.1.2.5 Canada: Neurotoxin Market, by End User, 2020-2028 (US$ Million)
      • 10.1.1.3 Mexico: Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 Mexico: Neurotoxin Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.3 Mexico: Neurotoxin Market, by Product Type, 2020-2028 (US$ Million)
        • 10.1.1.3.4 Mexico: Neurotoxin Market, by Application, 2020-2028 (US$ Million)
        • 10.1.1.3.5 Mexico: Neurotoxin Market, by End User, 2020-2028 (US$ Million)

11. North America Neurotoxins Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Merz Pharma GmbH & Co KGaA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 AbbVie Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Revance Therapeutics Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Ipsen SA
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Medytox Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Hugel Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Metabiologics
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦